Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Affinity maturation of CRISPR-engineered B cell receptors in vivo

CRISPR–Cas12a was used to directly replace mouse antibody variable chain genes with human versions in primary B cells. The edited cells underwent affinity maturation in vivo, improving the potency of HIV-1 and SARS-CoV-2 neutralizing antibodies without loss of bioavailability. Affinity maturation of edited cells also enables new vaccine models and adaptive B cell therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: In vivo affinity maturation of engineered B cell receptors.


  1. Rogers, G. L. & Cannon, P. M. Genome edited B cells: a new frontier in immune cell therapies. Molecul. Therapy 29, 3192–3204 (2021). A review article that describes B cell editing approaches and their applications.

    Article  CAS  Google Scholar 

  2. Hartweger, H. et al. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J. Exp. Med. 216, 1301–1310 (2019). One example of an intron-editing approach that introduced antibody heavy and light chains into the immunoglobulin heavy chain (IgH) intron locus.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yin, Y. et al. In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25. Proc. Natl Acad. Sci. USA 118, e2106203118 (2021). Applied CRISPR editing to create a library of antibody variants in a B cell line for subsequent selection.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. He, W. et al. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. Immunity 58, 2408–2424 (2023). A B cell engineering approach used to generate mice that emulate key features of human B cells for vaccine studies.

    Article  Google Scholar 

  5. Voss, J. E. et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. eLife 8, e42995 (2019). A pioneering paper in B cell engineering techniques that introduced a heavy-chain gene into human B cells with two CRISPR–Cas9 cuts.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Yin, Y. et al. In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nat. Biomed. Eng. (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Affinity maturation of CRISPR-engineered B cell receptors in vivo. Nat. Biomed. Eng 8, 341–342 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research